logo
Can Starbucks Stock Hit $108 in 2025?

Can Starbucks Stock Hit $108 in 2025?

Yahoo04-07-2025
In just over a year since Brian Niccol took the helm as CEO, Starbucks (SBUX) has faced increasing challenges, dimming the prospects of the company's ambitious "Back to Starbucks" initiative aimed at revitalizing growth. Launched with urgency, the plan was intended to spark renewed customer engagement and operational efficiency. But consumer behavior has shifted more than Starbucks expected. Visits remain soft, and same-store sales continue to slip.
Bernstein, however, is betting on patience and precision. The firm believes Starbucks' multi-year investment in labor — estimated between $1.5 billion and $2 billion over two years — will lay the groundwork for recovery.
'It's a Miracle': Nvidia CEO Says Their New Technology Takes 'AI Supercomputing to a Whole New Level'
AI Isn't Just About Nvidia: 2 Rising Stars in the Artificial Intelligence Race
UnitedHealth Stock Is One of the Worst-Performing S&P 500 Stocks in 2025. Should You Buy the Dip?
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.
Bernstein expects North American traffic to remain negative through 2025 before improving in 2026. By 2027 to 2028, same-store sales could climb 5%, with EBIT margins reaching 19% in North America and more than 15% company-wide.
The firm sees SBUX stock potentially doubling from its post-second-quarter lows, fueled by more than 20% EPS growth and a premium multiple. Even after a 15% rebound, Bernstein expects another 35% upside over the next two years.
Starbucks is the world's leading roaster and retailer of specialty coffee with more than more than 38,000 stores across the globe. With a market capitalization of $107 billion, it operates under several familiar banners such as Starbucks Coffee, Teavana, Seattle's Best Coffee, and Ethos.
SBUX stock's recent performance reflects renewed investor attention. Over the past 52 weeks, shares have risen 24%, including a 9% jump in just the past month.
The stock trades at 38 times forward adjusted earnings and 2.9 times sales, both valuations sitting above industry averages. That reflects investor confidence in the company's future earnings power.
Income-seeking investors will find further appeal in Starbucks' dividend record. The company pays an annualized forward dividend of $2.40 per share, offering a yield of 2.55%. It has raised its dividend for 14 consecutive years. The most recent payout of $0.61 per share was distributed on May 30 to shareholders of record as of May 16.
Starbucks announced its fiscal 2025 Q2 results on April 29, but the report did little to inspire confidence. Revenue came in at $8.76 billion, up 2.3% year-over-year (YOY) but short of the $8.82 billion Wall Street was expecting.
The same-store sales picture offered no relief, falling 1% during the quarter. The U.S. — the company's largest market — saw a 4% dip in transactions. While China managed a 4% increase in transaction volume, that was neutralized by a 4% drop in average ticket size, highlighting a shifting consumer dynamic in both markets.
Starbucks made a deliberate pivot during the quarter. It scaled back on expanding cold-brewing equipment to instead pour more resources into labor, a move it believes will generate more meaningful gains in order throughput and customer experience.
The decision, however, has come at a cost. Adjusted operating margin contracted sharply, down 460 basis points to 8.2%. Net income declined 50.3% YOY to $384.2 million. EPS plunged 50% YOY as well to $0.34 and failed to meet analysts' forecast of $0.48.
Still, CEO Brian Niccol remains confident. Niccol called the plan the right one, not just for near-term stabilization but also for unlocking long-term opportunity.
Forecasts reflect the current turbulence. Analysts expect third-quarter EPS to fall 31% YOY to $0.64. For fiscal 2025, the projection drops 25% to $2.48. A rebound is penciled in for fiscal 2026, with EPS expected to climb more than 20% to $2.99.
Bernstein continues to back SBUX stock with an 'Outperform' rating and has raised its price target from $90 to $100. The firm sees strengthening visibility around Starbucks' labor initiatives, margin stabilization, and earnings recovery as catalysts that could drive long-term upside.
Evercore ISI analyst David Palmer has followed suit, lifting his target price from $95 to $105. The revision reflects growing confidence in Starbucks' ability to execute through current headwinds. Both analysts align on one point: the turnaround is progressing, even if the financials have yet to fully catch up.
The broader analyst community holds a 'Moderate Buy' view. Of the 32 analysts covering the stock, 15 have issued a 'Strong Buy' rating, two rate it as a 'Moderate Buy,' 12 call the stock a 'Hold," one has marked it as a 'Moderate Sell', and two classify SBUX under 'Strong Sell.'
SBUX stock is already trading above its average price target of $91.50 yet still has a runway to climb. The Street-High target of $108 suggests a potential climb of 14% from current levels.
On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bank of America Reports Second Quarter 2025 Financial Results
Bank of America Reports Second Quarter 2025 Financial Results

Yahoo

time20 minutes ago

  • Yahoo

Bank of America Reports Second Quarter 2025 Financial Results

CHARLOTTE, N.C., July 16, 2025 /PRNewswire/ -- Bank of America reported its second quarter 2025 financial results today. The news release, supplemental filing and investor presentation can be accessed at Bank of America's Investor Relations website at A Form 8-K containing Bank of America's financial results is also available at the U.S. Securities and Exchange Commission's website at Investor Conference Call informationChief Executive Officer Brian Moynihan and Chief Financial Officer Alastair Borthwick will discuss the financial results in an investor conference call at 8 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international), and the conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can listen to live audio of the conference call and view the presentation slides by visiting the "Events and Presentations" section of the company's Investor Relations website. Replay information for Investor Conference CallInvestors can access replays of the investor conference call by visiting the Investor Relations website or by calling 1.800.934.4850 (U.S.) or 1.402.220.1178 (international) from noon on July 16 through 11:59 p.m. ET on July 25. Bank of AmericaBank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 69 million consumer and small business clients with approximately 3,700 retail financial centers, approximately 15,000 ATMs (automated teller machines) and award-winning digital banking with approximately 59 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 4 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and more than 35 countries. Bank of America Corporation stock is listed on the New York Stock Exchange (NYSE: BAC). For more Bank of America news, including dividend announcements and other important information, visit the Bank of America newsroom and register for news email alerts. Investors May Contact: Lee McEntire, Bank of AmericaPhone: Jonathan Blum, Bank of America (Fixed Income)Phone: Reporters May Contact: Jocelyn Seidenfeld, Bank of AmericaPhone: View original content to download multimedia: SOURCE Bank of America Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Many US employers plan to pare health benefits as weight-loss spending soars
Many US employers plan to pare health benefits as weight-loss spending soars

Yahoo

time20 minutes ago

  • Yahoo

Many US employers plan to pare health benefits as weight-loss spending soars

By Amina Niasse NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.

Johnson & Johnson: Q2 Earnings Snapshot
Johnson & Johnson: Q2 Earnings Snapshot

Yahoo

time20 minutes ago

  • Yahoo

Johnson & Johnson: Q2 Earnings Snapshot

NEW BRUNSWICK, N.J. (AP) — NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson (JNJ) on Wednesday reported second-quarter earnings of $5.54 billion. The New Brunswick, New Jersey-based company said it had profit of $2.29 per share. Earnings, adjusted for one-time gains and costs, came to $2.77 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $2.66 per share. The world's biggest maker of health care products posted revenue of $23.74 billion in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $22.8 billion. Johnson & Johnson expects full-year earnings in the range of $10.80 to $10.90 per share, with revenue in the range of $93.2 billion to $93.6 billion. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on JNJ at Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store